This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markman, M. Articles by Belinson, J. Search for Related Content PubMed PubMed Citation Articles by Markman, M. Articles by Belinson, J. Social Bookmarking                            What's this?

Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

From the Departments of Hematology/Medical Oncology and Gynecology/Obstetrics and the Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH; and The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Maurie Markman, MD, The University of Texas M.D. Anderson Cancer Center, Mail Box 121, Houston, TX 77030; e-mail: mmarkman{at}mdanderson.org

PURPOSE: Limited information is available regarding the influence of the duration of a prior response on the length of a subsequent response to platinum chemotherapy in recurrent ovarian cancer.

PATIENTS AND METHODS: We retrospectively reviewed the medical records of women with ovarian cancer treated at the Cleveland Clinic from 1993 through April 2003 who received two or more platinum-based regimens for recurrence of the malignancy. Patients were considered to have responded to second-line therapy if they satisfied specific criteria, including favorable effects on both measurable or assessable disease.

RESULTS: A total of 211 platinum-based regimens were administered to 176 women with recurrent ovarian cancer during this time period, with a response being observed in 125 treatment episodes (59%). Only four (3%) of 121 currently assessable secondary responses were of longer duration than the prior response in a specific individual. In three of these four cases, the platinum-based regimen used in the second-line approach included a drug that had not been used in that patient's primary chemotherapy program.

CONCLUSION: The length of a prior response to platinum-based therapy in ovarian cancer is highly predictive of the upper limit of the duration of response to a subsequent platinum program, assuming the same or similar drugs are used. Knowledge of this clinical parameter may assist in developing optimal management for an individual patient and may potentially be exploited in clinical trial designs examining novel maintenance strategies with both cytotoxic and cytostatic agents in women who achieve a secondary response to a platinum-based regimen.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Pecorelli, I. Ray-Coquard, O. Tredan, N. Colombo, G. Parma, G. Tisi, D. Katsaros, C. Lhomme, A. A. Lissoni, J. B. Vermorken, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes Ann. Onc., April 1, 2010; 21(4): 759 - 765. [Abstract] [Full Text] [PDF]

				R. M. Abou-Jawde and S. S. Oberoi Is Single-Agent Chemotherapy Acceptable in Platinum-Sensitive Relapsed Ovarian Cancer? J. Clin. Oncol., May 20, 2008; 26(15): 2602 - 2603. [Full Text] [PDF]

				G. Ferrandina, M. Ludovisi, G. Scambia, and S. Pignata In Reply J. Clin. Oncol., May 20, 2008; 26(15): 2603 - 2603. [Full Text] [PDF]

				C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748. [Abstract] [Full Text] [PDF]

				P. J. Sabbatini, G. Ragupathi, C. Hood, C. A. Aghajanian, M. Juretzka, A. Iasonos, M. L. Hensley, M. K. Spassova, O. Ouerfelli, D. R. Spriggs, et al. Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4170 - 4177. [Abstract] [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Onc., April 1, 2007; 18(4): 716 - 721. [Abstract] [Full Text] [PDF]

				J. Liu and U. Matulonis Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer J Natl Compr Canc Netw, October 1, 2006; 4(9): 947 - 953. [Abstract] [PDF]

				P. Sabbatini, J. Dupont, C. Aghajanian, F. Derosa, E. Poynor, S. Anderson, M. Hensley, P. Livingston, A. Iasonos, D. Spriggs, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res., September 15, 2006; 12(18): 5503 - 5510. [Abstract] [Full Text] [PDF]

				P. Sabbatini and D. R. Spriggs Consolidation for Ovarian Cancer in Remission J. Clin. Oncol., February 1, 2006; 24(4): 537 - 539. [Full Text] [PDF]